Substance / Medication

Elapegademase

Overview

Active Ingredient

elapegademase

RxNorm CUI

2059219

Indications

REVCOVI is indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.

Labeler: Chiesi USA, Inc.Updated: 2022-08-31T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Swiss type agammaglobulinemia

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:

Multi-Year Registry Study of Elapegademase Treatment in Patients With Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID) Requiring Enzyme Replacement Therapy.

Dorsey Morna J, Butte Manish J, Lieberman Jay A et al. · J Clin Immunol · 2025

PMID: 40140214ObservationalFull text (PMC)

Comparison of elapegademase and pegademase in ADA-deficient patients and mice.

Murguia-Favela L, Min W, Loves R et al. · Clin Exp Immunol · 2020

PMID: 31989577ObservationalFull text (PMC)

Treatment with Elapegademase Restores Immunity in Infants with Adenosine Deaminase Deficient Severe Combined Immunodeficiency.

Hicks Elizabeth Daly, Hall Geoffrey, Hershfield Michael S et al. · J Clin Immunol · 2024

PMID: 38676811Case ReportFull text (PMC)

Safety and efficacy of elapegademase in patients with adenosine deaminase deficiency: A multicenter, open-label, single-arm, phase 3, and postmarketing clinical study.

Onodera Masafumi, Uchiyama Toru, Ariga Tadashi et al. · Immun Inflamm Dis · 2023

PMID: 37506145ReviewFull text (PMC)

Long-Term Immune Reconstitution in ADA-Deficient Patients Treated With Elapegademase: A Real-World Experience.

Murguia-Favela Luis, Suresh Sneha, Wright Nicola A M et al. · J Allergy Clin Immunol Pract · 2023

PMID: 36736953Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Elapegademase (substance)
SNOMED CT: 782147005
UMLS CUI: C4731737
RxNorm CUI: 2059219
Labeler: Chiesi USA, Inc.

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.